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Background: In radiation oncology recurrence analysis is an important part in the evaluation process and clinical
quality assurance of treatment concepts. With the example of 9 patients with locally advanced pancreatic cancer
we developed and validated interactive analysis tools to support the evaluation workflow.
Methods: After an automatic registration of the radiation planning CTs with the follow-up images, the recurrence
volumes are segmented manually. Based on these volumes the DVH (dose volume histogram) statistic is calculated,
followed by the determination of the dose applied to the region of recurrence and the distance between the boost
and recurrence volume. We calculated the percentage of the recurrence volume within the 80%-isodose volume
and compared it to the location of the recurrence within the boost volume, boost + 1 cm, boost + 1.5 cm and
boost + 2 cm volumes.
Results: Recurrence analysis of 9 patients demonstrated that all recurrences except one occurred within the
defined GTV/boost volume; one recurrence developed beyond the field border/outfield. With the defined distance
volumes in relation to the recurrences, we could show that 7 recurrent lesions were within the 2 cm radius of the
primary tumor. Two large recurrences extended beyond the 2 cm, however, this might be due to very rapid growth
and/or late detection of the tumor progression.
Conclusion: The main goal of using automatic analysis tools is to reduce time and effort conducting clinical
analyses. We showed a first approach and use of a semi-automated workflow for recurrence analysis, which will be
continuously optimized. In conclusion, despite the limitations of the automatic calculations we contributed to
in-house optimization of subsequent study concepts based on an improved and validated target volume definition.
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In radiation oncology recurrence analysis is an import-
ant part in the evaluation process and clinical quality
assurance of treatment concepts. It can provide useful
information for subsequent dose-escalation strategies,
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reproduction in any medium, provided the orradiation doses, or identification of areas at high-risk
possibly amenable to surgical resection. However, it
involves handling a variety of significant datasets from
numerous information systems in different documenta-
tion styles. Especially when analyzing a large number of
patients, it can be immensely time consuming [1,2]. The
ultimate goal is the correlation of pre-treatment im-
aging, radiation treatment plans and follow-up imaging
with less effort, even in centers where multiple treat-
ment planning systems are in use. To date, no system
provides the base to allow such analyses with one mousetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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summing all patient data from treatment planning,
radiation plans and follow-up including imaging, lab
data and clinical evaluation. All information within
this system can be kept together to facilitate clinical ana-
lyses. To correlate imaging and treatment planning within
this system, to date, manual matching and evaluation is
required. Therefore, to support this process we adopted
several tools to accelerate the evaluation workflow for a
treatment planning and recurrence analysis. These tools
were integrated into the designed database workflow, and
validated on the example of patients with locally advanced
pancreatic cancer treated with radio-chemotherapy.
For pancreatic cancer it is known that about 30-40% of
patients are locally advanced and therefore not curatively
resectable [3]; therefore, strategies for downsizing are in
focus using different chemotherapeutic combinations or
chemoradiation. In line with several analyses we could
show previously that radiation and chemotherapy may lead
to downsizing and secondary resection in about 30-40% of
the patients [4]. However, much controversy exists about
target volume definition, from centers involving large
areas of lymphatic spread into the clinical target volume
(CTV) to strategies focusing on the gross tumor volume
(GTV) only [3,5,6]. Optimizing treatment volumes can be
performed based on recurrence and volume analysis,
therefore, this clinical case was taken to evaluate the
connected tools for recurrence and matching analysis.
Patterns of tumor progression can be determined by
calculating the distance of the recurrence from the primary
tumor, and the location of the recurrence in relation to the
target volumes and isodose volumes. Both factors provide
feedback on the question about adequate target volume
definition and safety margins for radiation therapy. With
respect to the emerging radiation techniques, e.g. stereotac-
tic body radiation therapy (SBRT) or particle therapy, to be
more precisely than conventional photon techniques, the
decision on how much tumor-surrounding normal tissue
should be irradiated becomes more important. Besides,
with the possibility of a high precise irradiation, higher
doses can be applied with the same radiation exposure for
organs at risk (OAR) and normal tissue.
Measuring the distance of the recurrence gives informa-
tion about where to expect the majority of recurrences in
general and consequently to what extent elective regions at
risk for subclinical tumor spread should be added to the
safety margin or CTV. Planning target volumes (PTV) are
added depending on the treatment technique, overall setup
and patient positioning.
The aim of this evaluation is to implement and connect
interactive analysis tools to support the analysis workflow
[7] and ultimately optimize patient treatment through
validation in a cohort of patients with locally advanced
pancreatic cancer.Methods
For validation of the developed data tools we randomly
chose 9 patients with locally advanced pancreatic cancer
treated with neoadjuvant radio-chemotherapy with
known progression after therapy, which developed local
recurrence. These patients are a subgroup of all patients
(n = 198) treated at the Department of Radiation Oncology
at the University Hospital Heidelberg between 2003-2010
(see Habermehl et. al. [4]). In one patient RT was delivered
as intensity-modulated radiation therapy (IMRT) and 8
patients had three-dimensional (3D) conformal radiation
therapy. All 9 patients had regular follow-up CT imaging
according to institutional guidelines [8]. Follow-up scans
were performed with a contrast-enhanced multislice CT
imaging in 30°-45° RAO (Right Anterior Oblique) position-
ing to reduce artifacts in the pancreatic head region [9].
For treatment planning, we acquired contrast-enhanced
multislice CT-imaging, with a slice thickness of 3 mm or
5 mm and fused it within the treatment planning system.
Target volume definition and treatment planning were
performed using the 3D treatment planning software
Oncentra MasterPlan (Nucletron, USA) or the IMRT
planning systems KonRad (Siemens OCS, Germany).
We defined the gross tumor volume (GTV) as the
macroscopically visible primary tumor. A clinical target vol-
ume (CTV) was defined including the GTV plus surround-
ing lymph nodes and areas of lymphatic spread adding
about 2-3 cm in all directions; for the boost volume a mar-
gin of 0.5-1 cm was added to the GTV. A planning target
volume (PTV) was added depending on the treatment
machine and patient setup of 3-5 mm. A median total
dose of 44.5 Gy to the PTV and 53.5 Gy to the boost in
median single doses of 1.86 Gy was applied.
For the recurrence analysis all images as well as the
radiation plans were gathered and stored in a documenta-
tion system [10] in addition to clinical patient data, e.g.
basic patient information and treatment data.
The analysis workflow has been established as follows:
after an automatic registration of the radiation planning
CTs with the follow-up images, the recurrence volumes
are segmented manually by a radiation oncologist. Based
on these volumes the DVH (dose volume histogram)
statistic is calculated, followed by the determination of
the dose applied to the region of recurrence and the
distance between the boost and recurrence volume.
The study is in compliance with the Helsinki Declar-
ation (Sixth Revision, 2008). A vote by the independent
Ethics Committee of the Medical Faculty, Heidelberg
has been obtained (Ref.-Nr.: S-483/2011).
Image registration
Image registration and analysis of the geometric vari-
ances is essential to determine the applied dose to the
recurrence. We used the AVID (analysis of variations in
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the geometric variances. The framework was created
with the goal to automatically analyze geometric and
dosimetric variances of large collections of patient data,
based on MatchPoint [11]. AVID allows exchanging the
registration method on demand. In the present evaluation,
a widely accepted mutual-information-based rigid registra-
tion method [12] is used, taking translational and rotational
changes of the moving images into account.
For our calculation, translational and rotational motions
along the left-right, anterior-posterior and superior-inferior
axes are determined with respect to the PTV and spinal
cord segmented on the planning CT. For each patient p ∈
{1,…,N} the follow-up CTs cctp ∈ {1,…,N} are registered
to the original planning CT. As a result, each determined
geometrical variance is represented by Tp,cct = (tx, ty, tz,
rpx, rpy, rpz, rx, ry, rz). While the first three values describe
the translational shifts, the values four to six specify the
rotation point and the last three values the rotation angles.
Segmentation
After registration the local pancreatic recurrence is
manually segmented on the registered follow-up CT
images. On each slice of the three-dimensional data
cube, the recurrence area is delineated.
Dose calculation
The AVID framework provides further dose analysis tools
for calculating dosimetric variances of defined volumes of
interest (VOI) from both the segmented structures on the
planning CT and the manually segmented recurrence
volume. AVID uses the RTToolbox [13] to determine
the dosimetric variances - a dedicated dose analysis library
developed at the German Cancer Research Center
(Heidelberg, Germany) containing analysis routines for
descriptive dose statistics parameters together with
DVHs. To ensure a precise dose analysis, voxelization is
done on several resolution levels, to ensure all calculations
have subvoxel accuracy.
Distance measuring & recurrence analysis
The automatic pre-registered CT images were revised and
again manually registered with focus on the surrounding
vessels (aorta, superior mesenteric artery, celiac trunc,
portal vein, hepatic arteries) of the initial tumor mass,
bone anatomy and location of organs at risk in close
proximity. For validating the automatic calculations
the boost volume was contoured by an experienced
radiation oncologist; additionally, using a manual en-
largement, the boost was expanded with circumferen-
tial margins of 1 cm, 1.5 cm and 2 cm. We correlated
the region of the recurrence with the original treat-
ment plan. Generally, for treatment planning, coverage
of the PTV by the 95%-isodose is attempted accordingto ICRU criteria. Since pure “local” failure is difficult
to distinguish from marginal recurrence in these patients,
we defined the 80%-isodose as our cut-off line for re-
currence description.
Results
In our group of 9 patients we processed CT scans with a
20° up to a 60° rotation. Consequently, pre-initialization
of the CT scans was part of the registration process.
After segmentation of the local recurrence the dose
evaluation was performed on follow-up CT scans. The
initial dose distribution derived from the original treat-
ment plan was correlated with the recurrence volume on
the follow-up images. We calculated the DVH statistics
of the 8 patients with 3D conformal radiation therapy
for the base and boost plan separately (see Table 1).
These plans were applied sequentially. We excluded the
IMRT patient as the boost dose is calculated into one
sum plan for radiation and we had no separate dose files
available for evaluation. Figure 1 shows the percentage of
the recurrence volume within the 80%-isodose volume.
The measurement of the location of the recurrence
within the boost volume, boost + 1 cm, boost + 1.5 cm
and boost + 2 cm volumes is described schematically in
Figure 2. Patient 9 had a biliary stent in the follow-up
CT but not initially. This made segmentation difficult
for the physician because of subsequent transposition of
anatomic structures in comparison to the initial CT
scan. Weight loss was clearly seen in all patients in the
follow-up CTs. Particularly the mesenteric and subcuta-
neous fat tissue decreased, which cannot be taken into
account very well by both the automatic algorithms and
the physician during registration.
Patient 7, 8 and 9 had large recurrences growing
within the boost volume/border and outfield up to
6.26 cm, 4.05 cm and 1.99 cm respectively (measured on
one representative axial slide). This can also be seen in
the calculated results in in Figure 1. Only 20%, 0% and
12% of the recurrence volume of patient 7, 8 and 9,
respectively, lie within the 80%-isodose volume.
Patient 3 had a severe deformation in the follow-up
CT scan (see Figure 3) compared to the planning CT.
That might be the reason for the different finding of the
physician and automatic calculation. In the validation
process, the physician found the recurrence to be within
the boost and boost + 1 cm volume. However, the auto-
matic algorithm calculated 84% in the PTV and only 15%
in the boost 80%-isodose volume.
The validation showed a very well match for patient 1
and 2 as well as 5 and 6 (cp. Table 2). For patient 1 and 2
the recurrence laid in the PTV 90% and 100%, respectively.
For patient 2 the algorithm calculated 98% match for the
boost volume; patient 1 had no boost VOI delineated for
calculation. Recurrences for patient 5 and 6 were in the
Table 1 Dose statistic of the recurrence volume grouped separately for the base and boost plan (patient 4 with IMRT is
excluded; patient 1 had no boost irradiation), calculated by the AVID dose algorithm























1 28 nd 79,31 71,08 31,02 53,15 51,17
2 24 5 48,89 48,89 42,15 43,77 42,80 47,99 4,35 9,20 8,59
3 24 5 59,26 49,65 19,38 43,49 40,89 8,97 0,29 8,74 3,35
5 23 5 311,04 311,04 37,16 43,27 41,02 75,49 4,18 9,30 8,95
6 24 5 29,93 29,93 39,65 43,90 42,59 28,35 1,14 9,25 8,91
7 24 5 66,58 37,28 16,41 44,59 37,63 13,14 0,17 9,27 1,69
8 24 5 221,82 17,42 0,75 40,53 2,86 0,00 0,05 2,66 0,15
9 25 3 104,76 34,13 3,74 47,90 32,94 12,95 0,15 5,64 3,17
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which correlates with the validation results to be within the
boost + 1 cm volume for patient 5 (algorithm 88% match);
and within the boost + 1.5 cm volume for patient 6
(algorithm 95% match).
Recurrence analysis demonstrated that all recurrences
except one occurred within the defined GTV/boost
volume; one recurrence developed beyond the field border/
outfield. With the defined distance volumes in relation
to the recurrences, we could show that most recurrent
lesions were within the 2 cm radius of the primary
tumor (cp. Figure 2). Two large recurrences extended
beyond the 2 cm, however, this might be due to very rapid
growth and/or late detection of the tumor progression.
Analysis of the spatial relationship of the recurrences
proved the concept that extension of the CTV/PTV into
the ventro-lateral regions of lymphatic spread of approxi-
mately 2 cm encloses the regions of tumor recurrence. No
growth dorsally in the region of the boost was observed;
therefore, no significant enlargement into this region
seems required. Additionally, no difference between the
lateral right-left sides could be shown.Figure 1 Diagram showing the percentage of the recurrence volume
calculated by the AVID dose algorithm.Discussion
The present analysis demonstrated that most recur-
rences of locally advanced pancreatic cancer develop
within the 2 cm radius of the primary tumor, thus a
CTV extension of 2 cm ventro-laterally is required to
address recurrences by enclosing high-risk regions.
Nevertheless, our study has several limitations mainly
due to morphological changes of the abdominal ana-
tomic structures and the CT scan setup. Pancreatic can-
cer patients are known to experience a significant loss of
body weight because of the underlying disease and the
multimodality treatment leading to a median loss of
approximately 13% of visceral adipose tissue [14]. This in
turn has direct impact on the topographic anatomy and
relationship of abdominal organs such as liver, pancreas,
stomach, intestine and kidneys.
Comparison and registration of different CT scans
recorded over several months is not a simple task and a
potential source of uncertainty. In our analysis, we
performed a rigid registration, as others showed to be
beneficial in pancreatic registration [15]. Nevertheless,
we don’t know if this method is sufficient enough;within the 80%-isodose volume of the base and boost plan,
Figure 2 Schematic diagram on the location of the recurrence
(colored structures) in the relation to the boost volume,
boost + 1 cm, boost + 1.5 cm and boost + 2 cm volumes
assessed during validation by the physician; the drawn PTV is
arbitrary representing common clinical relations.
Table 2 Overview on the location of the recurrence in
relation to the boost volume, boost + 1 cm, boost +
1.5 cm and boost + 2 cm volumes, delineated by the
radiation oncologist











6 X X X
7 X X X X
8 X X X X
9 X X X X
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Furthermore, as described in the methods section, follow-
up CT scans were acquired in a 30°-45° RAO position of
the patient according to our in-house standard [8,9,16].
This leads to a transposition of intra-abdominal organs to
the right side and affection of tumors adherent on mesen-
teric vessels. Even with careful manual registration of differ-
ent CT datasets certain impreciseness cannot be avoided.
However, an experienced radiation oncologist validated all
correlations to certify correct matching and relation of
boost and target volumes (cp. Table 2). This was the case in
all patients evaluated. Therefore, manual validation could
show overall excellent correlation with anatomical relations
of the boost to the treated target volumes.
For pancreatic tumors, a dose-response-relationship
has been shown in previous studies [17]. Together with
the pattern of recurrence evaluated in the presentFigure 3 CT scans of patient 3; left: planning CT, right: follow-up CT amanuscript as well as the data showing that all recur-
rences occurred infield within the 80%-isodose of the
high-dose boost treatment, further extension of target
volumes may not be of benefit. It even seems that
smaller margins dorso-laterally of around 1 cm, and
CTV extensions ventro-laterally only up to 2 cm maximum
are sufficient for the treatment of locally advanced
pancreatic cancer. These results are in accordance with
most recent consensus guidelines, except that dorso-lateral
margins, also with respect to sensitive OAR such as the
kidneys, might be reduced based on our data [3].
Physical and technical means of dose-escalation may
convert into an improvement of the therapeutic ratio.
Considering that, modern techniques such as stereotactic
body radiation therapy (SBRT), image guided radiation
therapy (IGRT) or also particle therapy should be
implemented in dose-escalation protocols. Preliminary
data have shown excellent local control and low toxicity
with single fraction of hypofractionated SBRT using differ-
ent techniques, even in combination with chemotherapyfter automatic registration with rotation and severe deformation.
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organ motion will be acquired, and methods of compensa-
tion will be available; therefore, compensation of organ
motion by separate target volumes such as internal target
volumes (ITV) or elastic compensation methods such as
tracking will be available in clinical routine.
Conclusion
In conclusion, the present work demonstrates feasibility
of a semi-automated system for recurrence analysis,
which will be continuously optimized to eliminate manual
steps in matching and segmentation. The system will be
directly connected to an existing patient database, to
provide a fully automated tool for fast analyses. Validation
on the cohort of patients with pancreatic cancer demon-
strated data well in accordance with previously published
data, and could contribute to in-house optimization of
subsequent study concepts based on an improved and
validated target volume definition.
Competing interests
There is no conflict of interest to report for this article.
Authors’ contributions
KAK selected the data and performed the analysis, drafted and wrote the
manuscript. DH segmented the recurrences and did the manual validation.
AJ developed the registration and dose calculation tools. LZ developed the
RTToolbox library. DH, JD and SEC were responsible for patient treatment
and care. SEC contributed substantially to conception and design. DH, AJ,
ROF and SEC reviewed/revised the manuscript. All authors read and
approved the final manuscript.
Author details
1Department of Radiation Oncology, Heidelberg University Hospital, Im
Neuenheimer Feld 400, 69120, Heidelberg, Germany. 2German Cancer
Research Center (dkfz), Im Neuenheimer Feld 280, 69120, Heidelberg,
Germany. 3Department of Medical Informatics, Heilbronn University,
Max-Planck-Str. 39, 74081, Heilbronn, Germany.
Received: 25 February 2013 Accepted: 4 June 2013
Published: 7 June 2013
References
1. Steil V, Röhner F, Schneider F, Wenz F, Lohr F, Weisser G: [Current requirements
for image management in radiotherapy]. Strahlenther Onkol 2012, 188:499–506.
2. Fietkau R, Budach W, Zamboglou N, Thiel H-J, Sack H, Popp W: Time
management in radiation oncology: development and evaluation of a
modular system based on the example of rectal cancer treatment. The
DEGRO-QUIRO trial. Strahlenther Onkol 2012, 188:5–11.
3. Huguet F, Goodman KA, Azria D, Racadot S, Abrams RA: Radiotherapy
technical considerations in the management of locally advanced
pancreatic cancer: American-French consensus recommendations.
Int J Radiation Oncology Biol Phys 2012, 83:1355–1364.
4. Habermehl D, Kessel KA, Welzel T, Hof H, Abdollahi A, Bergmann F, Rieken S,
Weitz J, Werner J, Schirmacher P, Büchler MW, Debus J, Combs SE:
Neoadjuvant chemoradiation with Gemcitabine for locally advanced
pancreatic cancer. Radiat Oncol 2012, 7:28–28.
5. van der Geld YG, van Triest B, Verbakel WFAR, van Sörnsen de Koste JR,
Senan S, Slotman BJ, Lagerwaard FJ: Evaluation of four-dimensional
computed tomography-based intensity-modulated and respiratory-gated
radiotherapy techniques for pancreatic carcinoma. Int J Radiation
Oncology Biol Phys 2008, 72:1215–1220.
6. Brown MW, Ning H, Arora B, Albert PS, Poggi M, Camphausen K, Citrin D:
A dosimetric analysis of dose escalation using two intensity-modulatedradiation therapy techniques in locally advanced pancreatic carcinoma.
Int J Radiation Oncology Biol Phys 2006, 65:274–283.
7. Kessel KA, Habermehl D, Bohn C, Jäger A, Floca RO, Zhang L, Bougatf N,
Bendl R, Debus J, Combs SE: Database supported electronic retrospective
analyses in radiation oncology: establishing a workflow using the
example of pancreatic cancer. Strahlenther Onkol 2012, 188:1119–1124.
8. Klauss M, Alt CD, Welzel T, Werner J, Büchler MW, Richter GM, Kauffmann
GW, Kauczor HU, Grenacher L: Multidetector CT evaluation of the course
of nonresectable pancreatic carcinomas with neoadjuvant therapy.
Pancreatology 2009, 9:621–630.
9. Richter GM, Simon C, Hoffmann V, DeBernardinis M, Seelos R, Senninger N,
Kauffmann GW: [Hydrospiral CT of the pancreas in thin section
technique]. Radiologe 1996, 36:397–405.
10. Kessel KA, Bougatf N, Bohn C, Habermehl D, Oetzel D, Bendl R, Engelmann
U, Orecchia R, Fossati P, Pötter R, Dosanjh M, Debus J, Combs SE: Connection
of European particle therapy centers and generation of a common
particle database system within the European ULICE-framework.
Radiat Oncol 2012, 7:115.
11. Floca RO: MatchPoint: on bridging the innovation gap between
algorithmic research and clinical use in image registration. In IFMBE
Proceedings. Volume 25/4. Edited by Dössel O, Schlegel W. Springer Berlin
Heidelberg; 2010:1105–1108.
12. Pluim JPW, Maintz JBA, Viergever MA: Mutual-information-based
registration of medical images: a survey. IEEE Trans Med Imaging 2003,
22:986–1004.
13. Zhang L, Hub M, Mang S, Thieke C, Nix O, Karger CP, Floca RO: Software for
quantitative analysis of radiotherapy: overview, requirement analysis and
design solutions. Comput Methods Programs Biomed 2013, 110:528–537.
14. Dalal S, Hui D, Bidaut L, Lem K, Del Fabbro E, Crane C, Reyes-Gibby CC, Bedi
D, Bruera E: Relationships among body mass index, longitudinal body
composition alterations, and survival in patients with locally advanced
pancreatic cancer receiving chemoradiation: a pilot study. J Pain
Symptom Manage 2012, 44:181–191.
15. Graf M, Simon D, Lemke A, Grünberg K, Mang S: Toward a non-invasive
screening tool for differentiation of pancreatic lesions based on intra-voxel
incoherent motion derived parameters. Toward a non-invasive screening
tool for differentiation of pancreatic lesions based on intra-voxel
incoherent motion derived parameters. Z Med Phys 2013, 23(1):46–55.
16. Grenacher L, Klauss M: [Computed tomography of pancreatic tumors].
Radiologe 2009, 49:107–123.
17. Golden DW, Novak CJ, Minsky BD, Liauw SL: Radiation dose > =54 Gy and
CA 19–9 response are associated with improved survival for
unresectable, non-metastatic pancreatic cancer treated with
chemoradiation. Radiat Oncol 2012, 7:156.
18. Schellenberg D, Kim J, Christman-Skieller C, Chun CL, Columbo LA, Ford JM,
Fisher GA, Kunz PL, Van Dam J, Quon A, Desser TS, Norton J, Hsu A, Maxim
PG, Xing L, Goodman KA, Chang DT, Koong AC: Single-fraction stereotactic
body radiation therapy and sequential gemcitabine for the treatment of
locally advanced pancreatic cancer. Int J Radiation Oncology Biol Phys
2011, 81:181–188.
19. Scorsetti M, Bignardi M, Alongi F, Fogliata A, Mancosu P, Navarria P,
Castiglioni S, Pentimalli S, Tozzi A, Cozzi L: Stereotactic body radiation
therapy for abdominal targets using volumetric intensity modulated arc
therapy with RapidArc: feasibility and clinical preliminary results. Acta
Oncol 2011, 50:528–538.
20. Didolkar MS, Coleman CW, Brenner MJ, Chu KU, Olexa N, Stanwyck E, Yu A,
Neerchal N, Rabinowitz S: Image-guided stereotactic radiosurgery for
locally advanced pancreatic adenocarcinoma results of first 85 patients.
J Gastrointest Surg 2010, 14:1547–1559.
21. Mahadevan A, Miksad R, Goldstein M, Sullivan R, Bullock A, Buchbinder E,
Pleskow D, Sawhney M, Kent T, Vollmer C, Callery M: Induction gemcitabine
and stereotactic body radiotherapy for locally advanced nonmetastatic
pancreas cancer. Int J Radiation Oncology Biol Phys 2011, 81:e615–22.
doi:10.1186/1748-717X-8-138
Cite this article as: Kessel et al.: Development and validation of
automatic tools for interactive recurrence analysis in radiation therapy:
optimization of treatment algorithms for locally advanced pancreatic
cancer. Radiation Oncology 2013 8:138.
